Patients with a confirmed diagnosis of IBD will be prospectively assessed on a yearly basis in order to assess relapse risk factors.
Disease activity will be assessed using the Mayo score for UC patients and CDAI for Crohn's disease and endoscopic activity will be assessed using the Mayo endoscopic subscore for UC patients and the Simple Endoscopic Score for Crohn's Disease for CD patients.
Serum and fecal biomarkers will be obtainted at each study visit (C-reactive protein, fecal calprotectin).
Data about current and past medication for IBD will also be gathered.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ulcerative colitis or Crohn's disease
age over 18
clinical remission
signed informed consent
You may not be if
pregnant women
refusal to sign informed consent
Clareo Health | Multimodal Approach in IBD Patients
